JP2002510621A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002510621A5 JP2002510621A5 JP2000541991A JP2000541991A JP2002510621A5 JP 2002510621 A5 JP2002510621 A5 JP 2002510621A5 JP 2000541991 A JP2000541991 A JP 2000541991A JP 2000541991 A JP2000541991 A JP 2000541991A JP 2002510621 A5 JP2002510621 A5 JP 2002510621A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- skin
- radiation
- exposure
- topical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 68
- 210000003491 Skin Anatomy 0.000 description 35
- 230000000699 topical Effects 0.000 description 22
- 150000004492 retinoid derivatives Chemical class 0.000 description 14
- 239000000516 sunscreening agent Substances 0.000 description 12
- 230000036570 collagen biosynthesis Effects 0.000 description 11
- 239000012049 topical pharmaceutical composition Substances 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 230000000475 sunscreen Effects 0.000 description 9
- 230000002238 attenuated Effects 0.000 description 8
- 230000003078 antioxidant Effects 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 229960005188 collagen Drugs 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- VTJXFTPMFYAJJU-UHFFFAOYSA-N 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile Chemical compound OC1=CC=C(C=C(C#N)C#N)C=C1O VTJXFTPMFYAJJU-UHFFFAOYSA-N 0.000 description 4
- XNEFYCZVKIDDMS-UHFFFAOYSA-N Avobenzone Chemical group C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 4
- 230000003042 antagnostic Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002194 synthesizing Effects 0.000 description 4
- 230000003313 weakening Effects 0.000 description 4
- 108010050808 Procollagen Proteins 0.000 description 3
- JKNOYWVMHPMBEL-UNXLUWIOSA-N (3Z)-2-amino-4-(3,4,5-trihydroxyphenyl)buta-1,3-diene-1,1,3-tricarbonitrile Chemical compound N#CC(C#N)=C(N)\C(C#N)=C\C1=CC(O)=C(O)C(O)=C1 JKNOYWVMHPMBEL-UNXLUWIOSA-N 0.000 description 2
- USOXQZNJFMKTKJ-XVNBXDOJSA-N (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide Chemical compound NC(=O)C(\C#N)=C\C1=CC=C(O)C(O)=C1 USOXQZNJFMKTKJ-XVNBXDOJSA-N 0.000 description 2
- YZOFLYUAQDJWKV-UHFFFAOYSA-N 2-[(3,4,5-trihydroxyphenyl)methylidene]propanedinitrile Chemical compound OC1=CC(C=C(C#N)C#N)=CC(O)=C1O YZOFLYUAQDJWKV-UHFFFAOYSA-N 0.000 description 2
- UOHFCPXBKJPCAD-UHFFFAOYSA-N 2-[(4-methoxyphenyl)methylidene]propanedinitrile Chemical compound COC1=CC=C(C=C(C#N)C#N)C=C1 UOHFCPXBKJPCAD-UHFFFAOYSA-N 0.000 description 2
- CTSHLCWTPAQAAB-FEPRGZSPSA-N 3-amino-2-[(Z)-(3-hydroxy-4-oxocyclohexa-2,5-dien-1-ylidene)methyl]-3-sulfanylprop-2-enenitrile Chemical compound NC(S)=C(C#N)\C=C1\C=CC(=O)C(O)=C1 CTSHLCWTPAQAAB-FEPRGZSPSA-N 0.000 description 2
- ULTTYPMRMMDONC-UHFFFAOYSA-N 5-[(2,5-dihydroxyphenyl)methyl-[(2-hydroxyphenyl)methyl]amino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2C(=CC=CC=2)O)CC=2C(=CC=C(O)C=2)O)=C1 ULTTYPMRMMDONC-UHFFFAOYSA-N 0.000 description 2
- 102100017089 COL1A2 Human genes 0.000 description 2
- 101710038301 COL1A2 Proteins 0.000 description 2
- 101700039191 EGFR Proteins 0.000 description 2
- 102100010782 EGFR Human genes 0.000 description 2
- 102000003688 G-protein coupled receptors Human genes 0.000 description 2
- 108090000045 G-protein coupled receptors Proteins 0.000 description 2
- ZCOLJUOHXJRHDI-CMWLGVBASA-N Genistin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 2
- 102000013404 Geranyltranstransferase Human genes 0.000 description 2
- 108010026318 Geranyltranstransferase Proteins 0.000 description 2
- MZOPWQKISXCCTP-UHFFFAOYSA-N Malonoben Chemical compound CC(C)(C)C1=CC(C=C(C#N)C#N)=CC(C(C)(C)C)=C1O MZOPWQKISXCCTP-UHFFFAOYSA-N 0.000 description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl methoxycinnamate Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- FIAFUQMPZJWCLV-UHFFFAOYSA-N Suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 2
- 229960005314 Suramin Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000002555 ionophore Substances 0.000 description 2
- 230000000236 ionophoric Effects 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 230000037333 procollagen synthesis Effects 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 1
- 229940045109 Genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- -1 genvustin A Chemical compound 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8043798P | 1998-04-02 | 1998-04-02 | |
| US60/080,437 | 1998-04-02 | ||
| PCT/US1999/007267 WO1999051220A1 (en) | 1998-04-02 | 1999-04-02 | Methods and compositions for reducing uv-induced inhibition of collagen synthesis in human skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002510621A JP2002510621A (ja) | 2002-04-09 |
| JP2002510621A5 true JP2002510621A5 (pt) | 2006-06-01 |
Family
ID=22157383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000541991A Pending JP2002510621A (ja) | 1998-04-02 | 1999-04-02 | ヒトの皮膚でのコラーゲン合成の紫外線で誘発される阻害を低減するための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1067920A4 (pt) |
| JP (1) | JP2002510621A (pt) |
| KR (1) | KR20010042422A (pt) |
| CN (1) | CN1303282A (pt) |
| AR (1) | AR018826A1 (pt) |
| AU (1) | AU740569B2 (pt) |
| BR (1) | BR9909899A (pt) |
| CA (1) | CA2326507A1 (pt) |
| HK (1) | HK1038514A1 (pt) |
| TW (1) | TWI234455B (pt) |
| WO (1) | WO1999051220A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100377397B1 (ko) * | 1999-12-23 | 2003-03-26 | 주식회사 대웅 | 레티놀 및 표피성장인자를 함유하는 피부보호 화장료 조성물 |
| JP2004504276A (ja) * | 2000-06-26 | 2004-02-12 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン | ヒトの皮膚の光老化を防止するためのｅｇｆ−ｒタンパク質チロシンキナーゼ抑制剤の使用 |
| JP4612180B2 (ja) * | 2000-12-19 | 2011-01-12 | 株式会社ヤクルト本社 | 皮膚外用剤 |
| KR100879558B1 (ko) * | 2007-07-31 | 2009-01-22 | 라이브켐 주식회사 | 디벤조파라디옥신 유도체를 유효성분으로 함유한 피부보호 및 개선제 |
| EP2987536A1 (en) * | 2008-03-31 | 2016-02-24 | Shiseido Co., Ltd. | Oral preparation, injection preparation, external skin preparation and cosmetic method for preventing or improving wrinkles |
| WO2009122540A1 (ja) * | 2008-03-31 | 2009-10-08 | 株式会社資生堂 | しわを防止または改善するための経口、注射、皮膚外用剤および美容方法 |
| EP2153814A1 (en) | 2008-08-05 | 2010-02-17 | Isdin S.A. | Use of compositions comprising urea |
| EP2153815A1 (en) | 2008-08-05 | 2010-02-17 | Isdin S.A. | Use of urea containing compositions |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4108880A (en) * | 1975-11-03 | 1978-08-22 | Johnson & Johnson | Esters of retinoic acid |
| JPS6061513A (ja) * | 1983-09-14 | 1985-04-09 | Sansho Seiyaku Kk | 化粧料 |
| US4810489A (en) * | 1986-12-04 | 1989-03-07 | Bristol-Myers Company | High oil phase pharmaceutical vehicles and sunscreen compositions having waterproof sun protection factors |
| GB8821129D0 (en) * | 1988-09-09 | 1988-10-12 | Unilever Plc | Cosmetic composition |
| JPH02142713A (ja) * | 1988-11-25 | 1990-05-31 | Shiseido Co Ltd | 皮膚外用剤 |
| US5051449A (en) * | 1991-02-27 | 1991-09-24 | Kligman Albert M | Treatment of cellulite with retinoids |
| JPH08245362A (ja) * | 1995-03-08 | 1996-09-24 | Seikagaku Kogyo Co Ltd | 紫外線損傷防御用外用剤 |
| US5851538A (en) * | 1995-12-29 | 1998-12-22 | Advanced Polymer Systems, Inc. | Retinoid formulations in porous microspheres for reduced irritation and enhanced stability |
| US5824702A (en) * | 1996-06-07 | 1998-10-20 | Mount Sinai School Of Medicine Of The City University Of New York | Genistein as a preventive against ultraviolet induced skin photodamage and cancer |
| US5690947A (en) * | 1996-08-30 | 1997-11-25 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Borage seed oil as an anti-irritant in compositions containing hydroxy acids or retinoids |
| AU5777498A (en) * | 1997-01-13 | 1998-08-03 | Cilag A.G. | Liposome-based topical tretinoin formulation |
| AUPP112497A0 (en) * | 1997-12-24 | 1998-01-22 | Novogen Research Pty Ltd | Compositions and method for protecting skin from UV induced immunosupression and skin damage |
-
1999
- 1999-03-23 TW TW088104581A patent/TWI234455B/zh not_active IP Right Cessation
- 1999-03-31 AR ARP990101496A patent/AR018826A1/es unknown
- 1999-04-02 CN CN99806699A patent/CN1303282A/zh active Pending
- 1999-04-02 EP EP99918456A patent/EP1067920A4/en not_active Withdrawn
- 1999-04-02 WO PCT/US1999/007267 patent/WO1999051220A1/en not_active Application Discontinuation
- 1999-04-02 JP JP2000541991A patent/JP2002510621A/ja active Pending
- 1999-04-02 KR KR1020007011003A patent/KR20010042422A/ko not_active Application Discontinuation
- 1999-04-02 AU AU36374/99A patent/AU740569B2/en not_active Ceased
- 1999-04-02 BR BR9909899-7A patent/BR9909899A/pt not_active IP Right Cessation
- 1999-04-02 CA CA002326507A patent/CA2326507A1/en not_active Abandoned
-
2002
- 2002-01-11 HK HK02100205.9A patent/HK1038514A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69737719D1 (de) | Substituierte gamma-aminobuttersäurederivate als arzneimittel | |
| PT1239849E (pt) | Formulacoes farmaceuticas que compreendem resveratrol e a sua utilizacao | |
| US20040072913A1 (en) | Use of cyclopamine in the treatment of psoriasis | |
| CA2166243C (fr) | Composition modulant l'apoptose comprenant un facteur influencant le taux intracellulaire de methional ou de malondialdehyde | |
| RS115104A (en) | Pramipexole once-daily dosage form | |
| CA2231561A1 (fr) | Utilisation d'un ligand agoniste specifique rar-.gamma. pour augmenter le taux d'apoptose | |
| JP2003526658A (ja) | パーキンソン病の治療用ｌ−ドーパ腎臓細胞トランスファー阻害剤を含む組成物 | |
| AU2016255707A1 (en) | Uses of cannabidiol for treatment of infantile spasms | |
| SK95998A3 (en) | Application of inhibitor for producing a medicament to prevent photoaging of undamaged human skin due to uvb irradiation exposure | |
| JP2002510621A5 (pt) | ||
| JP2012510963A (ja) | 結腸癌発生を予防または低減する方法 | |
| US20050058709A1 (en) | Methods for inhibiting photoaging of human skin using orally-administered agent | |
| Geiger | Retinoids and sebaceous gland activity | |
| Morimoio et al. | Photosensitivity to simvastatin with an unusual response to photopatch and photo tests. | |
| US5616618A (en) | Threo-3-(3,4-dihydroxyphenyl)serine analgesic composition | |
| BR0116433A (pt) | Métodos para redução de estresse crÈnico em mamìferos | |
| DE60028730D1 (de) | Multipartikuläre bisoprolol formulierung | |
| NO985676L (no) | Forbindelser med colchicinstruktur, deres anvendelse som legemidler og blan | |
| SG11201805480TA (en) | Methods of using caspase inhibitors in treatment of liver disease | |
| AU740569B2 (en) | Methods and compositions for reducing UV-induced inhibition of collagen synthesis in human skin | |
| EP1723952A1 (en) | Antiwrinkling preparation | |
| AU2020282051B2 (en) | Composition containing fluoxetine and vitamin D 3 or its derivatives and application thereof | |
| Mohammadi et al. | Evaluation the cognition-improvement effects of N-acetyl cysteine in experimental temporal lobe epilepsy in rat | |
| US20030003142A1 (en) | Composition and method for the treatment of pigmentation disorders | |
| US20040208836A1 (en) | Compositions for reducing UV-induced inhibition of collagen biosynthesis in human skin |